Treatment cuts exacerbation, rescue therapy risk in generalized MG

Uplizna (inebilizumab) reduced the frequency of disease exacerbations, or periods when symptoms worsen, and the need for rescue therapy in people with generalized myasthenia gravis (gMG). That’s according to a prespecified analysis of data from the global Phase 3 MINT clinical trial (NCT04524273), which showed that after six months of treatment, the risk of an […] The post Treatment cuts…